BioCardia, Inc. Deferred Tax Assets, Net of Valuation Allowance
BioCardia, Inc. (BCDA) had Deferred Tax Assets, Net of Valuation Allowance of $0 as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-24
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $0.00.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-24 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-24 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-25 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-25 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-24 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-24 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |